Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, $50 Price Target
Ascendiant Capital maintained a Buy rating on NRX Pharmaceuticals with a price target of $50.00, implying an upside of 1612.3% from the Sep 30 close.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.